Zhansheng Jiang

1.0k total citations
37 papers, 598 citations indexed

About

Zhansheng Jiang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Zhansheng Jiang has authored 37 papers receiving a total of 598 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Zhansheng Jiang's work include Lung Cancer Treatments and Mutations (5 papers), Ferroptosis and cancer prognosis (4 papers) and MicroRNA in disease regulation (3 papers). Zhansheng Jiang is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Ferroptosis and cancer prognosis (4 papers) and MicroRNA in disease regulation (3 papers). Zhansheng Jiang collaborates with scholars based in China, United States and France. Zhansheng Jiang's co-authors include Yinli Yang, Yanfang Yang, Ling Li, Cong Wang, Yu Zhang, Bin Wang, Xiubao Ren, Lin Gu, Jing Zhao and Yiran Mao and has published in prestigious journals such as Scientific Reports, Frontiers in Immunology and European Journal of Cancer.

In The Last Decade

Zhansheng Jiang

34 papers receiving 591 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhansheng Jiang China 14 279 232 141 136 79 37 598
Youqun Xiang China 17 347 1.2× 250 1.1× 73 0.5× 150 1.1× 64 0.8× 30 734
Chao Wu China 15 423 1.5× 193 0.8× 116 0.8× 263 1.9× 77 1.0× 62 768
Liangliang Bai China 17 348 1.2× 251 1.1× 141 1.0× 156 1.1× 85 1.1× 51 838
Yuting Wu China 14 351 1.3× 104 0.4× 113 0.8× 131 1.0× 60 0.8× 30 567
Fubin Feng China 16 379 1.4× 165 0.7× 147 1.0× 264 1.9× 74 0.9× 37 703
Silviu Constantin Bădoiu Romania 9 391 1.4× 176 0.8× 129 0.9× 177 1.3× 36 0.5× 20 720
Tiankui Qiao China 15 392 1.4× 168 0.7× 108 0.8× 149 1.1× 89 1.1× 39 691
Shuang Lin China 15 442 1.6× 163 0.7× 115 0.8× 255 1.9× 48 0.6× 34 778

Countries citing papers authored by Zhansheng Jiang

Since Specialization
Citations

This map shows the geographic impact of Zhansheng Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhansheng Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhansheng Jiang more than expected).

Fields of papers citing papers by Zhansheng Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhansheng Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhansheng Jiang. The network helps show where Zhansheng Jiang may publish in the future.

Co-authorship network of co-authors of Zhansheng Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Zhansheng Jiang. A scholar is included among the top collaborators of Zhansheng Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhansheng Jiang. Zhansheng Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guo, Y., Mingqing Zhang, Hui Liu, et al.. (2025). Comparative analysis of engineered-exosome delivered si-HER2 and trastuzumab in the treatment of HER2-positive gastric cancer. Investigational New Drugs. 43(4). 820–835. 1 indexed citations
2.
Jiang, Zhansheng, et al.. (2025). Anlotinib induced ferroptosis through the p53/xCT/GPX4 pathway in non-small cell lung cancer. Translational Oncology. 53. 102289–102289. 3 indexed citations
3.
Jiang, Zhansheng, Jiahe Wang, Mingyu Zhu, et al.. (2024). Utilizing a novel model of PANoptosis-related genes for enhanced prognosis and immune status prediction in kidney renal clear cell carcinoma. APOPTOSIS. 29(5-6). 681–692. 14 indexed citations
4.
Wang, Cong, Zhansheng Jiang, Mingjie Zhang, et al.. (2024). Prolonged administration of the granisetron transdermal delivery system reduces capecitabine plus oxaliplatin regimen induced nausea and vomiting. BMC Cancer. 24(1). 867–867. 1 indexed citations
5.
Bai, Changsen, Wenxin Li, Gang Zhao, et al.. (2024). Circ_0006949 as a potential non-invasive diagnosis biomarker promotes the proliferation of NSCLC cells via miR-4673/GLUL axis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1870(6). 167234–167234. 1 indexed citations
6.
Jiang, Zhansheng, et al.. (2024). Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer. Gynecologic Oncology. 187. 1–11. 3 indexed citations
7.
Li, Zengxun, Lei Zhu, Zheng Han, et al.. (2022). Serum IL‐35 levels is a new candidate biomarker of cancer‐related cachexia in stage IV non‐small cell lung cancer. Thoracic Cancer. 13(5). 716–723. 9 indexed citations
8.
Wang, Wenxian, Gen Lin, Yue Hao, et al.. (2022). Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study. European Journal of Cancer. 174. 21–30. 10 indexed citations
9.
Hao, Yue, Xingxiang Pu, Liping Wang, et al.. (2022). The prognostic impact of immune checkpoint inhibitors for the treatment of pulmonary sarcomatoid carcinoma: A multicenter retrospective study. Neoplasma. 69(6). 1437–1444. 6 indexed citations
10.
Yang, Yinli, et al.. (2020). Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunology Immunotherapy. 69(12). 2523–2532. 83 indexed citations
11.
Wang, Ruixia, et al.. (2019). Expression of OPN3 in lung adenocarcinoma promotes epithelial‐mesenchymal transition and tumor metastasis. Thoracic Cancer. 11(2). 286–294. 21 indexed citations
12.
Jiang, Zhansheng, et al.. (2018). A case of tonsillar metastasis from breast cancer and literature review. The Breast Journal. 24(5). 833–835. 1 indexed citations
13.
Yang, Yanfang, Zhansheng Jiang, Ning Ma, et al.. (2018). MicroRNA-223 Targeting STIM1 Inhibits the Biological Behavior of Breast Cancer. Cellular Physiology and Biochemistry. 45(2). 856–866. 29 indexed citations
14.
Lan, Lan, Yue Wang, Bin Wang, et al.. (2018). Rhamnetin induces apoptosis in human breast cancer cells via the miR‑34a/Notch‑1 signaling pathway. Oncology Letters. 17(1). 676–682. 38 indexed citations
15.
Jiang, Zhansheng, et al.. (2018). Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis. Journal of Cancer Research and Therapeutics. 14(12). 957–957. 4 indexed citations
16.
Yang, Yanfang, Zhansheng Jiang, Lili Chang, et al.. (2017). Expression of STIM1 is associated with tumor aggressiveness and poor prognosis in breast cancer. Pathology - Research and Practice. 213(9). 1043–1047. 25 indexed citations
17.
Jiang, Zhansheng, et al.. (2017). Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. Biomedicine & Pharmacotherapy. 96. 378–383. 119 indexed citations
18.
Li, Yanwei, et al.. (2016). Martine delayed morphine tolerance associated with inhibited the expression of permeability-glycoprotein. Zhonghua shiyan waike zazhi. 33(6). 1625–1628.
19.
Jiang, Zhansheng, et al.. (2015). Study of the methylation patterns of the EGFR gene promoter in non-small cell lung cancer. Genetics and Molecular Research. 14(3). 9813–9820. 8 indexed citations
20.
Jiang, Zhansheng, et al.. (2014). [Efficacy of lapatinib versus trastuzumab in neoadjuvant therapy of HER-2 positive breast cancer: a meta-analysis].. PubMed. 94(48). 3854–8. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Youqun Xiang Breakdown of academic impact, for papers by Chao Wu Breakdown of academic impact, for papers by Liangliang Bai Breakdown of academic impact, for papers by Yuting Wu Breakdown of academic impact, for papers by Fubin Feng Breakdown of academic impact, for papers by Silviu Constantin Bădoiu Breakdown of academic impact, for papers by Tiankui Qiao Breakdown of academic impact, for papers by Shuang Lin
Rankless by CCL
2026